Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Thursday

Neumora Therapeutics (NASDAQ:NMRA) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Neumora Therapeutics to post earnings of ($0.46) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA opened at $1.62 on Thursday. The company’s 50-day moving average is $3.76 and its 200 day moving average is $9.10. Neumora Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $21.00. The company has a market capitalization of $261.73 million, a P/E ratio of -0.87 and a beta of 2.54.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $29.00 to $4.00 in a report on Thursday, January 2nd. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday, January 2nd. Bank of America reduced their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.